Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
In development: Guidance, quality standards and advice
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (1 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (5)
Type
Type
Guidance (303)
Guidance programme
(
1 selected
)
Guidance programme
Clinical guidelines (29)
Diagnostics guidance (7)
Health technology evaluations (17)
Highly specialised technologies guidance (10)
Interventional procedures guidance (21)
Medical technologies guidance (13)
NICE guidelines (32)
Public health guidelines (1)
Technology appraisal guidance (303)
Apply filters
Showing 26 to 50 of 303
Sort by
Title
Date
Apply sorting
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]
Technology appraisal guidance
TBC
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]
Technology appraisal guidance
TBC
Avelumab for previously treated platinum-resistant ovarian cancer ID1497
Technology appraisal guidance
TBC
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]
Technology appraisal guidance
TBC
Avelumab with axitinib for untreated advanced renal cell carcinoma (MA review of TA645) [ID6294]
Technology appraisal guidance
25 June 2025
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]
Technology appraisal guidance
TBC
Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6212
Technology appraisal guidance
5 March 2025
Belantamab mafodotin with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6211
Technology appraisal guidance
19 March 2025
Belzutifan for previously treated advanced renal cell carcinoma [ID6154]
Technology appraisal guidance
TBC
Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis ID6266
Technology appraisal guidance
16 July 2025
Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen ID6462
Technology appraisal guidance
11 September 2025
Bevacizumab gamma for treating wet age-related macular degeneration [ID6320]
Technology appraisal guidance
4 December 2024
Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145]
Technology appraisal guidance
20 February 2019
BI 907828 for untreated dedifferentiated advanced liposarcoma [ID6296]
Technology appraisal guidance
TBC
Bimatoprost implant for treating open angle glaucoma or ocular hypertension when topical treatments are unsuitable [ID6180]
Technology appraisal guidance
TBC
Bimekizumab for treating moderate to severe hidradenitis suppurativa [ID6134]
Technology appraisal guidance
TBC
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease [ID6405]
Technology appraisal guidance
26 March 2025
Botulinum toxin type A for treating upper or lower limb focal spasticity associated with stroke [ID768]
Technology appraisal guidance
TBC
Brentuximab vedotin with doxorubicin, dacarbazine and vinblastine for previously untreated late-stage classical Hodgkin lymphoma (including Review of TA594) [ID6334]
Technology appraisal guidance
28 January 2025
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments [ID6325](review of TA677)
Technology appraisal guidance
10 September 2025
Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]
Technology appraisal guidance
TBC
Cabotegravir for preventing HIV-1 in adults and young people [ID6255]
Technology appraisal guidance
29 January 2025
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]
Technology appraisal guidance
24 May 2019
Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment ID6474
Technology appraisal guidance
TBC
Cabozantinib with nivolumab and ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma [ID6330]
Technology appraisal guidance
TBC
Previous page
1
Current page
2
3
4
…
13
Page
2
of
13
Next page
Results per page
10
25
50
All
Back to top